Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  Gallbladder cancer
Stage/Subtype:  metastatic gallbladder cancer
Trial Type:  Treatment
Results 1-25 of 26 for your search:
Start Over
A Study of Nivolumab, Compared to Placebo, in Patients With Bladder or Upper Urinary Tract Cancer, Following Surgery to Remove the Cancer
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: CA209-274, NCI-2016-00764, 2014-003626-40, NCT02632409
A Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: BBI608-201, NCI-2014-01566, NCT01325441
Genetic Analysis-Guided Dosing of FOLFIRABAX in Treating Patients with Advanced Gastrointestinal Cancer
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: IRB14-0595, NCI-2014-02407, NCT02333188
Tumor Infiltrating Lymphocytes and Aldesleukin after Chemotherapy and Pembrolizumab in Treating Patients with Metastatic Cancers
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 10-C-0166, NCI-2013-01461, 100166, P09567, 306343, NCT01174121
Regorafenib in Treating Patients With Advanced or Metastatic Biliary Tract Cancer Who Failed First-Line Chemotherapy
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: UPCI 13-100, NCI-2014-01117, NCT02053376
Single Agent Regorafenib in Refractory Advanced Biliary Cancers
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: MCC-17651, NCI-2014-00956, 14.02.0015, NCT02115542
Ponatinib Hydrochloride in Treating Patients with Advanced Biliary Cancer with FGFR2 Fusions
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: MC1345, NCI-2014-02075, NCT02265341
Gemcitabine Hydrochloride, Cisplatin, and Nab-Paclitaxel in Treating Patients with Advanced or Metastatic Biliary Cancers
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 2014-0524, NCI-2015-00578, NCT02392637
Dasatinib in Treating Patients with Liver Cancer That Is Metastatic or Cannot Be Removed by Surgery and with an IDH Mutation
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 15-007, NCI-2015-00938, CA180-603, NCT02428855
Ramucirumab in Treating Patients with Advanced or Metastatic, Previously Treated Biliary Cancers That Cannot Be Removed by Surgery
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 2015-0393, NCI-2015-01442, NCT02520141
Thermal Ablation and Spine Stereotactic Radiosurgery in Treating Patients with Spine Metastases at Risk for Compressing the Spinal Cord
Status: Active
Phase: Phase II
Type: Natural history/Epidemiology, Treatment
Age: 18 and over
Trial IDs: 2015-0223, NCI-2016-00683, NCT02713269
Copanlisib, Gemcitabine, and Cisplatin in Treating Patients with Advanced Cholangiocarcinoma
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: MCC-18435, NCI-2016-01029, NCT02631590
A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 16329, NCI-2016-01171, I3O-MC-JSBF, 2015-004699-31, NCT02711553
Study of Nivolumab in Patients With Advanced Refractory Biliary Tract Cancers
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: MCC-18684, NCI-2016-01424, NCT02829918
Oncolytic HSV-1 rRp450 in Treating Patients with Primary Liver Cancer
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 09-042, NCI-2010-01930, NCT01071941
Combination Chemotherapy in Treating Patients With Previously Untreated Locally Advanced or Metastatic Gastrointestinal Malignancies
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 12-0033, NCI-2012-00585, 12-0033-AM010, NCT01643499
A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Advanced Gastrointestinal Cancer
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: BBI608-246, NCI-2015-00892, NCT02024607
Alisertib and Combination Chemotherapy in Treating Patients with Gastrointestinal Tumors
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 9824, NCI-2014-02475, VICC GI1536, NCT02319018
Afatinib Dimaleate and Capecitabine in Treating Patients with Advanced Refractory Solid Tumors, Pancreatic Cancer or Biliary Cancer
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 19 and over
Trial IDs: 9078, NCI-2015-00684, NCT02451553
Multicenter, Open-label, Clinical and Pharmacokinetic Study of PM060184 in Combination With Gemcitabine in Selected Patients With Advanced Solid Tumors
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: PM60184-A-003-14, NCI-2015-01510, 2014-002943-16, NCT02533674
Recombinant EphB4-HSA Fusion Protein with Standard Chemotherapy Regimens in Treating Patients with Advanced or Metastatic Solid Tumors
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 0S-15-5, NCI-2015-00987, NCT02495896
CD8+ T Cell Therapy and Pembrolizumab in Treating Patients with Metastatic Gastrointestinal Tumors
Status: Not yet active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 2015-0152, NCI-2016-01058, NCT02757391
A Study of LY3039478 in Participants With Advanced or Metastatic Solid Tumors
Status: Not yet active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 16209, NCI-2016-01101, I6F-MC-JJCD, 2015-004421-14, NCT02784795
6,8-Bis(benzylthio)octanoic Acid in Treating Patients with Advanced or Metastatic Cholangiocarcinoma that Cannot Be Removed by Surgery
Status: Active
Phase: No phase specified
Type: Treatment
Age: 18 to 80
Trial IDs: CCCWFU 59212, NCI-2013-00063, NCT01766219
Tremelimumab with Transarterial Chemoembolization, Radiofrequency Ablation, Cryosurgery, or Stereotactic Body Radiation Therapy in Treating Patients with Advanced Liver or Biliary Tract Cancer
Status: Active
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 13-C-0120, NCI-2013-01557, 130120, P121113, NCT01853618
Start Over